Primenenie silimarina v klinicheskoy gepatologii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hepatoprotective drugs find a wide application in the treatment of liver diseases. Silymarin occupies a prominent place in this group of drugs. Currently, the mechanisms of its multiform actions are studied in detail: antihepatotoxic, antioxidant, anti-inflammatory, anti-allergic and anti-fibrotic effects provide a variety of its effects on liver function. Silymarin is widely used in alcoholic liver disease, chronic hepatitis of HCV-etiology, non-alcoholic steatohepatitis and toxic liver diseases.

Full Text

Restricted Access

About the authors

A. S Toporkov

References

  1. Матвеев А.В., Коняева Е.И., Курченко В.П. и др. Гепатопротективные свойства силимарина. Эксп.клин. гастроэнтерол. 2011;2:130-36.
  2. Буеверов А.О., Маевская М.В., Ивашкин В.Т. Дифференцированный подход к лечению алкогольных поражений печени. Росс.журнал гастроэнтерол., гепатол., колопроктол., 2005;5:4-9.
  3. Ивашкин В.Т., Маевская М.В., Буеверов А.О., Богомолов П.О. Рациональная фармакотерапия в гепатологии. М., 2009. 296 с.
  4. Luper S. A review of plants used in the treatment of liver disease. Part 1. Altern.Med.R. 1998;3(6):410-21.
  5. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63.
  6. Schrieber S.J., Wen Z.,Vourvahis M., et al. The pharmacokinrtics of silymarin in altered in patiens with hepatitis C virus and nonalcoholic fatty liver disease and correkates with plasma caspase-3/7 activity. Drug Metab. Dispos. 2008;36(9):1909-16.
  7. Щекотихина А.С. Гепатопротективные свойства флаволигнагов. Труды Белорусского у-та, 2009;4(1):27-48.
  8. Lineret H., Brault A., Vallerend D., et al. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfuion liver injury. J. Ethnophamacology. 2007;115(3):507-14.
  9. Charagozioo M., Moayedi B., Zakerinia M., et al. Combined therapy of silymarin and desferrioxamine in patients with beta-talassemia major-a randomized double-blind clinical trial. Fundam. Clin. Pharmacol. 2009;23(3):359-65.
  10. Muriel P., Moreno M.G., Hemandez M.C., et al. Resolution of liver fibrosis in chronic CC14 administration in the rat after discontinuation of treatment effect of silymarin, silibinin,colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 2005;96:375-80.
  11. Loguersio C., Festi D. Silybin and the liver. Fom basic research to clinical practice. Wond J. Gastroenterol. 2011;17(18):2288-301.
  12. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of silymarin treatment in patients ith cirrhosis of the liver. J. Hepatol. 1989;9(1):105-13.
  13. Feher J., Deak G., Muzes G., et al. Liver-protective action of silymarin therapy in chronic alcogolic liver diseases Orv.Hetil. 1989;130(51): 2723-27.
  14. Rambaldi A., Jacobs B.P., Gluud C. Milk thistie for alcogolic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. 2007;4:CDOO3620.
  15. Salmi H.A., Sama S. Effects of silymarin on chemical,functional and morphological alterations of the liver. A double-blind controlled studu. Scand. J. Gastroenterol. 1982;17(4):517-21.
  16. Saller R., Meire R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63.
  17. Saller R., Brignoli R., Melzer J., et al. An updated systematic review with meta-analyses for the clinical evidence of silymarin. Forsch. Komplementmed. 2008;15(1):9-20.
  18. Юрьев К.Л. Силимарин: эффекты и механизмы действия, клиническая эффективность и безопасность. Ч. 1. Эффекты и механизмы действия. Укр. мед. часопис. 2010;2(76):71-5.
  19. El-Kumary S.S., Shardel M.D., Abdel-Hamid M., et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009;16(5):391-400.
  20. Seeff L.B., Curto T.M., Szabo G., et al. Herbal product use by persons enrolled in the hepatitis C. Antiviral long-term treatment against cirrhosis. Thal. Hepatology. 2008;47:605-12.
  21. Biermer M., Berg T. Rapid suppressionof hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology. 2009;137:390-91.
  22. Ferenci P., Scheiser T.M., Kerschner H., et al. Silibi nin is a potent antiviral agent in patients with chronoc hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561-67.
  23. Hawke R.L., Schrieber S.J., Soule T.A., et al. Silymarin ascending multiple oral dosing phase. 1 study in noncirrhotic patients with chronic hepatitis C. J.Clin. Pharmacol. 2010; 50(4):434-39.
  24. Pradhan S.C., Girish C. Hepatoprotective herbal drug silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 2006;124(5):491-504.
  25. Par A., Roth E., Miseta A., et al. Effects of supplementation with the antioxidant flavonoid, silymarin in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebocontrolled double-blind study. Orv. Hetil. 2009;150(2):73-9.
  26. Federico A., Trappoliere M., Tuccilo C., et al. A new silybin vitamin e-phospholipid complex improves insulin resistance and liver damage in patients with non -alcoholic fatty liver disease preliminary observations. Gut. 2006; 55(6):901-02.
  27. Abenavoli L., Aviello G., Capasso R., et al. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat. Mon. 2011;1(3):173-77.
  28. Kumagi T., Heathcote E.J. Primary biliary cirrhosis Orphanet. J. Rare Dis. 2008;3:1-17.
  29. Gazak R., Walterova D., Kren V. Silybin and silymarin-new and emerging applications in mеdicine. Curr. Med.Chem. 2007;14:315-38.
  30. Salhanick S.D.,Wax P.M., Schneider S.M., et al. Comparative treatment of alpha-amanitin poisoning with N-acetylcystejne,benzylpenicilli n,cimetidin,thioctic acid and silybin in a murine model. Ann. Emerg. Med. 2008;52:184-85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media